For example, the analysis of the frequencies of mutations of NPM1, FLT3-ITD, FLT3-TKD and CEBPA in a cohort of 1321 adult patients of all ages with AML, has shown a significant decrease of NPM1 and FLT3 mutations with age, with a significant impact on CR rates in older patients (75–86% for patients <60 years vs. 55–63% for patients >60 years) [17]. This evidence concerns the gene FLT3 and acute myeloid leukemia.